Answers are grounded in this paper and cite their sources.
Campylobacter is a zoonotic bacterium and the leading cause of bacterial gastroenteritis in humans and animals in several countries. It is managed through antibiotic therapy, including macrolides (erythromycin) and fluoroquinolones (ciprofloxacin), which is the drug of choice. The aim of this study was to investigate the phenotypic resistance profile and the molecular determinants potentially associated with fluoroquinolone resistance in Campylobacter isolates obtained from diarrhoeal faeces of children under 5 years of age in Makokou, Gabon. The susceptibility of 116 Campylobacter isolates was evaluated against ciprofloxacin and pefloxacin (second-generation fluoroquinolones) and levofloxacin (third-generation fluoroquinolone). The genetic basis of any resistance to these compounds was determined by screening the chromosomal gyrA gene and the plasmid qnrA, qnrB and qnrS genes, which were detected using conventional PCR. Phenotypically, all isolates are resistant to all compounds (100%). Molecularly, the gyrA gene was amplified in 94.0% of the isolates, the qnrS gene in 51.7% (60/116), the qnrB gene in 4.3% (5/116), and the qnrA gene 0.0%. Furthermore, 52.6% (61/116) carried both the gyrA gene and at least one of the qnr genes detected. Campylobacter isolates showed total resistance to fluoroquinolones, suggesting a probable therapeutic deadlock with these molecules, possibly mediated by qnr genes. The detection of these genetic determinants suggests that plasmid-mediated transmission may contribute to the spread of resistant Campylobacter in various environments. However, given that conventional PCR only confirms the presence of the gyrA gene and not the specific mutations within the quinolone resistance-determining region (QRDR) that confer resistance, additional genomic sequencing is required to fully elucidate the mechanisms of resistance. This study consequently highlights the importance of monitoring the epidemiological evolution and resistance of Campylobacter isolates in order to optimize therapeutic management strategies.
No takes yet. Share an insight, caveat, or question.
Yala et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: